Literature DB >> 12110248

Influenza and the work of the World Health Organization.

M E Kitler1, P Gavinio, D Lavanchy.   

Abstract

Before World War I, influenza was not considered a particularly serious problem. The great pandemic of 1918-1919 changed all that, and the possibility that such a catastrophe could occur again has conditioned all subsequent developments. In epidemiological terms, the hallmark of an influenza is the excess mortality that it causes combined with an enormous burden of ill-health that saps the energy of individuals, families and communities throughout the whole world. In order to engage in influenza prevention and control, the global influenza surveillance network was set up by World Health Organization (WHO) in 1948 as a worldwide alert system for the identification of new influenza viruses, gathering information from 110 participating laboratories in 82 countries and four WHO Collaborating Centers for Influenza reference and research: Centers for Disease Control and Prevention, Atlanta (USA), National Institute for Medical Research, London (UK), WHO Collaborating Centre for Influenza Reference and Research, Melbourne (Australia) and the National Institute for Infectious Diseases, Tokyo (Japan). This network helps WHO to monitor influenza activity all over the world and provides the organization with the viral isolates and information it requires to decide which new virus strains will be used to produce influenza vaccines during the following season. Each year, information about the isolates over the previous 12 months is analyzed and used to determine the composition of the influenza vaccine to be administered during the coming influenza season both for the northern and southern hemisphere. If necessary, the recommendations for the southern hemisphere differ from the ones formulated for the northern hemisphere vaccine. The information supplied by this network enables the organization to regularly update its World Wide Web (WWW) site (FluNet), which reports on the situation of diseases. This network will also enable the WHO to detect a new influenza pandemic as early as possible.

Mesh:

Substances:

Year:  2002        PMID: 12110248     DOI: 10.1016/s0264-410x(02)00121-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Changing perceptions: of pandemic influenza and public health responses.

Authors:  Adam Kamradt-Scott
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

2.  Challenges in antigenic characterization of circulating influenza A(H3N2) viruses during the 2011-2012 influenza season: an ongoing problem?

Authors:  Athanasios Kossyvakis; Vasiliki Pogka; Aggeliki Melidou; Afroditi Moutousi; Georgia Gioula; Antonios Kalliaropoulos; Maria Exindari; Mary Emmanouil; Elina Horefti; Georgia Spala; Adam Meijer; Nikolaos Malisiovas; Andreas F Mentis
Journal:  J Clin Microbiol       Date:  2015-02-18       Impact factor: 5.948

3.  Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine.

Authors:  Fengjia Chen; Ho Seong Seo; Hyun Jung Ji; Eunji Yang; Jung Ah Choi; Jae Seung Yang; Manki Song; Seung Hyun Han; Sangyong Lim; Jae Hyang Lim; Ki Bum Ahn
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

Review 4.  History and current trends in influenza virus infections with special reference to Sri Lanka.

Authors:  R A M Rafeek; M V M Divarathna; F Noordeen
Journal:  Virusdisease       Date:  2017-07-18

5.  Evaluation of Southern Hemisphere influenza vaccine recommendations.

Authors:  Stephanie A Richard; Cécile Viboud; Mark A Miller
Journal:  Vaccine       Date:  2010-02-11       Impact factor: 3.641

6.  Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.

Authors:  Jianhua Sui; Wenhui Li; Anjeanette Roberts; Leslie J Matthews; Akikazu Murakami; Leatrice Vogel; Swee Kee Wong; Kanta Subbarao; Michael Farzan; Wayne A Marasco
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.

Authors:  Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Jesica Swanstrom; Ralph S Baric
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

Review 8.  Lessons from 40 years' surveillance of influenza in England and Wales.

Authors:  D M Fleming; A J Elliot
Journal:  Epidemiol Infect       Date:  2007-11-30       Impact factor: 2.451

9.  Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin.

Authors:  Katherine A Richards; Francisco A Chaves; Frederick R Krafcik; David J Topham; Christopher A Lazarski; Andrea J Sant
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

10.  Nanorobot Hardware Architecture for Medical Defense.

Authors:  Adriano Cavalcanti; Bijan Shirinzadeh; Mingjun Zhang; Luiz C Kretly
Journal:  Sensors (Basel)       Date:  2008-05-06       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.